231 related articles for article (PubMed ID: 15702812)
1. Short-term and long-term tolerability of rofecoxib in patients with prior reactions to nonsteroidal anti-inflammatory drugs.
Nettis E; Colanardi MC; Ferrannini A; Tursi A
Ann Allergy Asthma Immunol; 2005 Jan; 94(1):29-33. PubMed ID: 15702812
[TBL] [Abstract][Full Text] [Related]
2. Tolerance of nonsteroidal anti-inflammatory drug-sensitive patients to the highly specific cyclooxygenase 2 inhibitors rofecoxib and valdecoxib.
Sánchez-Borges M; Caballero-Fonseca F; Capriles-Hulett A
Ann Allergy Asthma Immunol; 2005 Jan; 94(1):34-8. PubMed ID: 15702813
[TBL] [Abstract][Full Text] [Related]
3. Use of ketoprofen oral challenges to detect cross-reactors among patients with a history of aspirin-induced urticaria.
Asero R
Ann Allergy Asthma Immunol; 2006 Aug; 97(2):187-9. PubMed ID: 16937749
[TBL] [Abstract][Full Text] [Related]
4. [Tolerability of a selective cyclooxygenase-2-inhibitor (rofecoxib) in patients with intolerance reactions to nonsteroidal anti-inflammatory agents].
Zollner TM; Ahlbach S; Kaufmann R; Boehncke WH
Dtsch Med Wochenschr; 2001 Apr; 126(14):386-8. PubMed ID: 11332239
[TBL] [Abstract][Full Text] [Related]
5. Safety of high-dose rofecoxib in patients with aspirin-exacerbated respiratory disease.
Woessner KM; Simon RA; Stevenson DD
Ann Allergy Asthma Immunol; 2004 Oct; 93(4):339-44. PubMed ID: 15521369
[TBL] [Abstract][Full Text] [Related]
6. Lack of cross-reactivity between rofecoxib and aspirin in aspirin-sensitive patients with asthma.
Stevenson DD; Simon RA
J Allergy Clin Immunol; 2001 Jul; 108(1):47-51. PubMed ID: 11447381
[TBL] [Abstract][Full Text] [Related]
7. Safety of selective COX-2 inhibitors in aspirin/nonsteroidal anti-inflammatory drug-intolerant patients: comparison of nimesulide, meloxicam, and rofecoxib.
Bavbek S; Celik G; Ozer F; Mungan D; Misirligil Z
J Asthma; 2004 Feb; 41(1):67-75. PubMed ID: 15046380
[TBL] [Abstract][Full Text] [Related]
8. Risk factors for acetaminophen and nimesulide intolerance in patients with NSAID-induced skin disorders.
Asero R
Ann Allergy Asthma Immunol; 1999 Jun; 82(6):554-8. PubMed ID: 10400483
[TBL] [Abstract][Full Text] [Related]
9. [The selective cyclooxygenase-2 inhibitor celecoxib is a safe alternative in patients with pseudo-allergic reactions to nonsteroidal anti-inflammatory drugs].
Ahlbach S; Usadel KH; Kaufmann R; Boehncke WH
Med Klin (Munich); 2003 Apr; 98(5):242-4. PubMed ID: 12721666
[TBL] [Abstract][Full Text] [Related]
10. Tolerability of rofecoxib in patients with adverse reactions to nonsteroidal anti-inflammatory drugs: a study of 216 patients and literature review.
Perrone MR; Artesani MC; Viola M; Gaeta F; Caringi M; Quaratino D; Romano A
Int Arch Allergy Immunol; 2003 Sep; 132(1):82-6. PubMed ID: 14555862
[TBL] [Abstract][Full Text] [Related]
11. Tolerability of three selective cyclo-oxygenase-2 inhibitors, meloxicam, celecoxib and rofecoxib in NSAID-sensitive patients.
Senna G; Bilò MB; Antonicelli L; Schiappoli M; Crivellaro MA; Bonadonna P; Dama AR
Eur Ann Allergy Clin Immunol; 2004 Jun; 36(6):215-8. PubMed ID: 15329003
[TBL] [Abstract][Full Text] [Related]
12. Rofecoxib, as a safe alternative for acetyl salicylic acid/nonsteroidal anti-inflammatory drug-intolerant patients.
Bavbek S; Celik G; Pasaoglu G; Misirligil Z
J Investig Allergol Clin Immunol; 2006; 16(1):57-62. PubMed ID: 16599250
[TBL] [Abstract][Full Text] [Related]
13. Safety of cyclooxygenase 2 inhibitors and increased leukotriene synthesis in chronic idiopathic urticaria with sensitivity to nonsteroidal anti-inflammatory drugs.
Zembowicz A; Mastalerz L; Setkowicz M; Radziszewski W; Szczeklik A
Arch Dermatol; 2003 Dec; 139(12):1577-82. PubMed ID: 14676074
[TBL] [Abstract][Full Text] [Related]
14. Floctafenine: a valid alternative in patients with adverse reactions to nonsteroidal anti-inflammatory drugs.
Giuseppe P; Antonino R; Alessandro DB; Donato Q; Marina DF; Donatella P; Francesca G; Alberto V
Ann Allergy Asthma Immunol; 1997 Jan; 78(1):74-8. PubMed ID: 9012626
[TBL] [Abstract][Full Text] [Related]
15. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
Bresalier RS; Sandler RS; Quan H; Bolognese JA; Oxenius B; Horgan K; Lines C; Riddell R; Morton D; Lanas A; Konstam MA; Baron JA;
N Engl J Med; 2005 Mar; 352(11):1092-102. PubMed ID: 15713943
[TBL] [Abstract][Full Text] [Related]
16. Safety of celecoxib in patients with adverse skin reactions to acetaminophen (paracetamol) and nimesulide associated or not with common non-steroidal anti-inflammatory drugs.
Liccardi G; Salzillo A; Piccolo A; Senna G; Piscitelli E; D'Amato M; D'Amato G
Eur Ann Allergy Clin Immunol; 2005 Feb; 37(2):50-3. PubMed ID: 15859361
[TBL] [Abstract][Full Text] [Related]
17. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
Sowers JR; White WB; Pitt B; Whelton A; Simon LS; Winer N; Kivitz A; van Ingen H; Brabant T; Fort JG;
Arch Intern Med; 2005 Jan; 165(2):161-8. PubMed ID: 15668361
[TBL] [Abstract][Full Text] [Related]
18. The use of nimesulide in patients with acetylsalicylic acid and nonsteroidal anti-inflammatory drug intolerance.
Bavbek S; Celik G; Ediger D; Mungan D; Demirel YS; Misirligil Z
J Asthma; 1999 Dec; 36(8):657-63. PubMed ID: 10609620
[TBL] [Abstract][Full Text] [Related]
19. Safety of parecoxib in patients with nonsteroidal anti-inflammatory drug-induced urticaria or angioedema.
Colanardi MC; Nettis E; Traetta P; Daprile C; Fitto C; Aloia AM; Di Leo E; Ferrannini A; Vacca A
Ann Allergy Asthma Immunol; 2008 Jan; 100(1):82-5. PubMed ID: 18254487
[TBL] [Abstract][Full Text] [Related]
20. Intracranial hypertension induced by rofecoxib.
Jacob S; Rajabally YA
Headache; 2005 Jan; 45(1):75-6. PubMed ID: 15663617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
